Eucrates Biomedical Acquisition Corp.
EUCRU
NASDAQ Capital Market10.02
USD
-0.07
- -
CIK
0001822929
ISIN
VGG3141W1142
CUSIP
G3141W114
Return %
Stock
S&P500
1Y
1.01
18.44
3Y
0.20
63.65
5Y
0.20
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Parag Phoolchand Saxena MBA, MS
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 250 West 55th Street New York City NY United States of America 10019
- IPO Date
- Oct 6, 2020
- CIK
- 0001822929
- Similar Companies
- Business
- Eucrates Biomedical Acquisition Corp. is a U.S.-based special purpose acquisition company (SPAC) focused on the biomedical and healthcare industry. The company targets North American and European healthcare companies with the potential to drive transformational change through the convergence of biomedicine and data science. Its core business model involves raising capital through initial public offerings to facilitate mergers, share exchanges, asset acquisitions, or other business combinations with existing biomedical entities. Eucrates does not manufacture or sell products directly but serves as a financial vehicle to acquire or merge with businesses in biotechnology, healthcare, medical technology, diagnostics, and data-driven drug development sectors. Founded in 2020 and headquartered in New York, Eucrates Biomedical Acquisition Corp. completed its initial public offering (IPO) in October 2020, raising $100 million. The IPO units include ordinary shares and redeemable warrants, traded under the ticker symbols EUCRU, EUCR, and EUCRW on the Nasdaq Capital Market. The company is overseen by management with expertise in biomedical innovation and data science, aiming to support companies that accelerate drug discovery, real-world evidence analysis, novel biologics, medical devices, diagnostics, and AI-enabled medical technology. Recent major developments indicate that Eucrates Biomedical Acquisition Corp. has not completed any mergers, acquisitions, or notable strategic business combinations as of late 2025. The company’s financial health exhibits credit risk fluctuations with elevated default probability readings signaling heightened financial stress, yet no significant operational changes or new product launches have been reported. Eucrates continues to focus on identifying and acquiring targets aligned with its strategy of fostering biomedical progress through investment rather than direct operational involvement. Eucrates operates primarily as an investment and acquisition entity within the biomedical and healthcare sectors, leveraging financial instruments to enable transformative business combinations. Its strategy centers on leveraging data science to enhance medical innovation, targeting markets in North America and Europe. Despite ongoing market challenges and credit risk fluctuations, Eucrates maintains its position as a financial facilitator for emerging biomedical and healthcare companies seeking capital and market access. No subsidiaries or parent company affiliations have been publicly disclosed, and the organization remains a publicly traded SPAC on Nasdaq since its 2020 IPO.